Letter to the Editor of Obesity Pillars from the American Board of Obesity Medicine.

Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: DB and KAG are the ABOM Executive Director and Medical Director, respectively. JK is Chair and EPW is Vice-Chair of the ABOM Board of Directors. KAG, EPW and JK are ABOM Diplomates. DB reports no other relationships. KAG also reports the following relationships: Novo Nordisk Inc (consulting/advisory; grant funding) and Eli Lilly and Company (consulting/advisory). EPW also reports the following relationships: 10.13039/100015519WW International Inc (grant funding); 10.13039/100011302Children's Hospital Foundation (grant funding); and Foundation for Advanced Education in the Sciences (speaking/lecture fees). JK also reports the following relationships: Gila Therapeutics (consulting/advisory); GI Dynamics (consulting/advisory); Found Health (consulting/advisory; equity/stocks); Digma Medical (equity/stocks); and Servier Laboratories (paid expert testimony).